AU2001250962A1 - Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors - Google Patents

Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors

Info

Publication number
AU2001250962A1
AU2001250962A1 AU2001250962A AU5096201A AU2001250962A1 AU 2001250962 A1 AU2001250962 A1 AU 2001250962A1 AU 2001250962 A AU2001250962 A AU 2001250962A AU 5096201 A AU5096201 A AU 5096201A AU 2001250962 A1 AU2001250962 A1 AU 2001250962A1
Authority
AU
Australia
Prior art keywords
xaa
bmp
res
morphogenic protein
morphogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250962A
Other languages
English (en)
Inventor
Lentsha Nathaniel Ramoshebi
Ugo Ripamonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of AU2001250962A1 publication Critical patent/AU2001250962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001250962A 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors Abandoned AU2001250962A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09540466 2000-03-31
US09/540,466 US20030104977A1 (en) 2000-03-31 2000-03-31 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
PCT/US2001/009451 WO2001074379A2 (fr) 2000-03-31 2001-03-23 Procedes pour induire l'angiogenese au moyen de proteines morphogeniques et de facteurs stimulateurs

Publications (1)

Publication Number Publication Date
AU2001250962A1 true AU2001250962A1 (en) 2001-10-15

Family

ID=24155572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250962A Abandoned AU2001250962A1 (en) 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors

Country Status (6)

Country Link
US (1) US20030104977A1 (fr)
EP (1) EP1267910A2 (fr)
JP (1) JP2003528922A (fr)
AU (1) AU2001250962A1 (fr)
CA (1) CA2402586A1 (fr)
WO (1) WO2001074379A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363965C (fr) 1991-03-11 2010-05-18 Curis, Inc. Morphogenese induite par des proteines
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
JP5819733B2 (ja) * 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与
SG173634A1 (en) * 2009-02-12 2011-09-29 Stryker Corp COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
EP3007719B1 (fr) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Procédés et compositions pour augmenter la neurogenèse et l'angiogenèse
IL293766B2 (en) 2016-01-06 2023-08-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose loading and reduces hepatosteatosis
WO2019144053A1 (fr) 2018-01-19 2019-07-25 President And Fellows Of Harward College Variants de gdf11 et leurs utilisations
CN114470162B (zh) * 2022-01-28 2023-02-03 浙江大学 Gdf6及其过表达试剂在制备心肌细胞保护剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
CA2071137A1 (fr) * 1991-07-10 1993-01-11 Clarence C. Lee Composition et methode pour la revitalisation du tissu cicatriciel
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
ATE238417T1 (de) * 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
BR9704385A (pt) * 1996-08-19 1999-05-11 Hoechst Ag Novas antibióticos de polieno 3874 h1 a h6 processos para a sua preparação e uso
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
AU1276399A (en) * 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
US6027917A (en) * 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions

Also Published As

Publication number Publication date
CA2402586A1 (fr) 2001-10-11
WO2001074379A3 (fr) 2002-03-21
EP1267910A2 (fr) 2003-01-02
US20030104977A1 (en) 2003-06-05
WO2001074379A2 (fr) 2001-10-11
JP2003528922A (ja) 2003-09-30

Similar Documents

Publication Publication Date Title
Reddi Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens
US7638495B2 (en) Peptides as solubilizing excipients for transforming growth factor β proteins
Thomas Fibroblast growth factors
Roberts et al. The transforming growth factor-β s
Cao et al. Development of normal and injury-induced gene expression of aFGF, bFGF, CNTF, BDNF, GFAP and IGF-I in the rat retina
US9365617B2 (en) Activated collagen scaffold materials and their special fused active restoration factors
US20070191276A1 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
JP2002505851A (ja) 骨形態形成タンパク（ｂｍｐ）−１７およびｂｍｐ−１８の組成物
JPH08503198A (ja) Ｏｐ−３誘導形態形成
US7253254B1 (en) Polypeptide variants with increased heparin-binding capacity
US20030104977A1 (en) Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
US20020132334A1 (en) Cloning, expression and uses of dorsalin-1
US20080293654A1 (en) Therapeutic methods using Smads
US20100168029A1 (en) Methods for treating bone tumors
Fox The role of growth factors in tissue repair III: fibroblast growth factor
AU7619100A (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
US7476654B2 (en) Method for modulating, regulating and/or stabilizing angiogenesis
US20070122396A1 (en) Morphogenic proteins and stimulatory factors in gene therapy